1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mercury Bio Inc. currently has 1 pending office action in its patent portfolio. This active matter is assigned to 1 distinct examiner, concentrating the current prosecution efforts on a single individual. The data shows 0 distinct art units associated with the current pending actions, which may reflect a specific administrative status. This lack of art unit diversity suggests a highly specialized or unique filing status.
MARIA MARVICH is the busiest examiner for the company, overseeing the busiest examiner pending office action. This single action accounts for the entirety of the portfolio's active workload. With only a single examiner involved, the current prosecution landscape is highly centralized, requiring focused interaction with this official to resolve the outstanding matter. The absence of multiple examiners simplifies the coordination of legal responses for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18949090 | TARGETED EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTICS | MARVICH, MARIA | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18949090 | TARGETED EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTICS | MARVICH, MARIA | — | §112DP | Non-Final OA | — | Pending | Nov 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMercury Bio Inc. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Maria Marvich has the most, with 1 of Mercury Bio Inc.'s pending office actions.